Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen

被引:16
作者
Goel, Madhu Mati [1 ]
Agrawal, Dhamita [1 ]
Natu, S. M. [1 ]
Goel, Apul [2 ]
机构
[1] CSM Med Univ, Dept Pathol, Lucknow 226003, Uttar Pradesh, India
[2] CSM Med Univ, Dept Urol, Lucknow 226003, Uttar Pradesh, India
关键词
Hepsin; immunohistochemistry; prostate cancer; BIOMARKERS; DIAGNOSIS; PROGNOSIS; CELLS; GENE;
D O I
10.4103/0377-4929.85078
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Hepsin (HPN), a type II trans-membrane serine protease, has been reported to be one of the most up regulated genes in prostate cancer. The aim of the present study was to find out immuno-histochemistry based phenotypic expression of HPN in formalin fixed paraffin embedded sections of prostate cancer compared with that in benign prostatic hyperplasia, in a prospective clinical setting, to know the differential status of HPN expression in benign and malignant prostatic disease. Materials and Methods: Tissue biopsies of histologically proven cases of prostatic cancers (48), benign prostatic hyperplasia (42), benign prostatic hyperplasia with prostatic intraepithelial neoplasia (7) and 4 cases of benign prostatic hyperplasia with prostatitis, were subjected to immunohistochemical staining with HPN antibody by strepavidin biotin method. Results: Hepsin expression was 100% in prostate carcinoma, 11.9% (5/42) in benign prostatic hyperplasia, 57.14% (4/7) in benign prostatic hyperplasia with prostatic intraepithelial neoplasia (PIN), and none in benign prostatic hyperplasia with prostatitis. Hepsin staining showe higher expression in high grade tumor in comparison to low grade tumor. Conclusions: Positive immunohistochemical expression of hepsin in cent percent cases of prostate cancer cases is intriguing, underscoring the significance of hepsin gene expression in prostate cancer.
引用
收藏
页码:476 / 481
页数:6
相关论文
共 16 条
[11]   Prostate specific antigen: A decade of discovery - What we have learned and where we are going [J].
Polascik, TJ ;
Oesterling, JE ;
Partin, AW .
JOURNAL OF UROLOGY, 1999, 162 (02) :293-306
[12]   Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer [J].
Sardana, Girish ;
Dowell, Barry ;
Diamandis, Eleftherios P. .
CLINICAL CHEMISTRY, 2008, 54 (12) :1951-1960
[13]  
Srikantan V, 2002, CANCER RES, V62, P6812
[14]   The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? [J].
Stamey, TA ;
Caldwell, M ;
McNeal, JE ;
Nolley, R ;
Hemenez, M ;
Downs, J .
JOURNAL OF UROLOGY, 2004, 172 (04) :1297-1301
[15]   Hepsin and prostate cancer [J].
Wu, Qingyu ;
Parry, Gordon .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :5052-5059
[16]   Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture [J].
Xuan, JA ;
Schneider, D ;
Toy, P ;
Lin, R ;
Newton, A ;
Zhu, Y ;
Finster, S ;
Vogel, D ;
Mintzer, B ;
Dinter, H ;
Light, D ;
Parry, R ;
Polokoff, M ;
Whitlow, M ;
Wu, QY ;
Parry, G .
CANCER RESEARCH, 2006, 66 (07) :3611-3619